The Semaglutide (Ozempic®) and Tirzepatide (Mounjaro®) is an excellent breakthrough in the management of obesity. Though these medications were initially intended to treat type 2 diabetes, they have also shown promise in managing weight. Ozempic is a GLP 1 receptor agonist, while Mounjaro is a GIP and GLP 1 receptor agonist and they primarily act on GLP-1 (and GIP for tirzepatide) pathways to control appetite and slow down digestion process resulting in weight loss. Many clinical trials have been conducted internationally to check their effect on weight management, Some of these trials have shown average reductions (15–22%) of body weight, which is significant as compared to lifestyle modification alone 1, 2 . In the SURMOUNT-1 trial, patients without any history of diabetes lost up to 22.5% of body weight over a period of 72 weeks 1, whereas in SURPASS-2 trial , patients with type 2 diabetes showed HbA1c reductions of up to 2.3% and lost up to 12.4 kg weight lost. These results are better as compared to semaglutide 3. Obesity is closely linked to diabetes, heart disease, and certain cancers, therefore a more justifiable access and provision of these medicines could help to reduce long-term healthcare burdens. Obesity increases the risk of diabetes, heart disease, and some cancers. Provision of these weight reducing medicines can help to reduce long term health care cost. Keywords: Semaglutide, Tirzepatide, Obesity, GLP1, GIP, SURMOUNT-1 Trial, SURPASS-2 Trial, Diabetes, HbA1c
Tabinda Ashfaq (Mon,) studied this question.